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a CAMPaign with Measles Vaccination
(RECAMP-MV) and Real-life Effect of a
CAMPaign with Oral Polio Vaccination
(RECAMP-OPV) on mortality and morbidity
among children in rural Guinea-Bissau
A. Varma1,2,3* , A. K. G. Jensen1,4, S. M. Thysen1,2,5, L. M. Pedersen1,2, P. Aaby1,2,3 and A. B. Fisker1,2,3*Abstract
Background: Measles and oral polio vaccinations may reduce child mortality to an extent that cannot be explained
by prevention of measles and polio infections; these vaccines seem to have beneficial non-specific effects. In the
last decades, billions of children worldwide have received measles vaccine (MV) and oral polio vaccine (OPV) through
campaigns. Meanwhile the under-five child mortality has declined. Past MV and OPV campaigns may have contributed
to this decline, even in the absence of measles and polio infections. However, cessation of these campaigns, once their
targeted infections are eradicated, may reverse the decline in the under-five child mortality. No randomized trial has
assessed the real-life effect of either campaign on child mortality and morbidity. We present the research protocol of
two concurrent trials: RECAMP-MV and RECAMP-OPV.
Methods: Both trials are cluster-randomized trials among children registered in Bandim Health Project’s rural health
and demographic surveillance system throughout Guinea-Bissau. RECAMP-MV is conducted among children aged 9–
59months and RECAMP-OPV is conducted among children aged 0–8months. We randomized 222 geographical
clusters to intervention or control clusters. In intervention clusters, children are offered MV or OPV (according to age at
enrolment) and a health check-up. In control clusters, children are offered only a health check-up. Enrolments began in
November 2016 (RECAMP-MV) and March 2017 (RECAMP-OPV). We plan 18,000 enrolments for RECAMP-MV with an
average follow-up period of 18months and 10,000 enrolments for RECAMP-OPV with an average follow-up period of
10months. Data collection is ongoing. The primary outcome in both trials is non-accidental death or non-accidental
first non-fatal hospitalization with overnight stay (composite outcome). Secondary outcomes are: non-accidental death,
repeated non-fatal hospitalizations with overnight stay, cause-specific primary outcome, outpatient visit, and illness. We
obtained ethical approval from Guinea-Bissau and consultative approval from Denmark.
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Discussion: Cluster randomization and minimum risk of loss to follow-up are strengths, and no placebo a limitation.
Our trials challenge the understanding that MV and OPV only prevent measles and polio, and that once both infections
are eradicated, campaigns with MV and OPV can be phased out without negative implications on child health and
survival.
Trial registration: NCT03460002.Background
The common public health understanding is that vac-
cines protect against their target infections and do little
else. However, an increasing body of evidence challenges
this understanding. Studies from low-income countries
suggest that the live measles vaccine (MV) and the live
oral polio vaccine (OPV) reduce the under-five child
mortality to an extent that cannot be explained by
prevention of measles or polio infections; both vaccines
seem to have what is termed beneficial non-specific
effects (NSEs) [1]. In a systematic review commissioned
by the World Health Organization’s (WHO) Strategic
Advisory Group of Experts on Immunizations (SAGE) it
was concluded in 2014 that, “There was consistent evi-
dence of a beneficial effect of measles vaccine (…)” on
child mortality. This conclusion was based on four
randomized trials and 18 observational studies [2] but
SAGE called for more research [3]. Though the effect of
OPV was not included in the review, OPV also seems to
have beneficial NSEs: In two trials, where infants were
randomised to OPV or no OPV at birth, OPV was
associated with a 32% lower infant mortality in both tri-
als [4, 5]. Observational studies also indicate that chil-
dren receiving OPV with a non-live vaccine have better
survival than children receiving the non-live vaccine only
[6, 7]. We respond to SAGE’s call for more research by
assessing the NSEs of an MV campaign and an OPV
campaign.
In the last decades, billions of children have received
MV and OPV through campaigns implemented world-
wide with the goal to ultimately eradicate measles and
polio infections [8, 9]. The campaigns aim at reaching all
children in a broad age-group regardless of pre-
campaign vaccination status, also children who are not
reached through routine vaccination program services.
The campaigns can increase population immunity
against the viruses rapidly, thereby interrupting virus
transmission, which leads to herd protection [10, 11].
The under-five child mortality has declined on a global
scale [12] in the same period as campaigns with MV and
OPV have been conducted. Thus, we suggest that past
MV and OPV campaigns may have efficiently contrib-
uted to reduce the under-five child mortality given their
presumed beneficial NSEs, even in the absence of mea-
sles and polio infections. Cessation of MV and OPVcampaigns after eradication of their targeted infections
may therefore reverse the declining trend in the under-
five child mortality.
No randomized trial has assessed the real-life effect of
an MV campaign or an OPV campaign on child mortal-
ity. Two observational studies were published after
WHO’s SAGE review, and both support that MV cam-
paigns among children reduced the under-five mortality.
In a before/after study among 8000 children, mortality
in the year following an MV campaign was 20% (4–34%)
lower compared with the year prior to the campaign,
even after censoring measles deaths (17% (0–31%)) [13].
Another study compared mortality in MV campaign par-
ticipants (5633) with non-participants (1006) in the year
following the campaign, and mortality was found to be
72% (23–90%) lower among participants; no deaths were
measles related [14]. In both studies, children who were
also measles vaccinated through routine vaccination pro-
gram services seemed to additionally benefit from the
MV campaign [13, 14]. Similarly, OPV campaigns may
reduce child mortality considerably. Among children
followed in seven trials of vaccines or vitamin A sup-
plements, an OPV campaign was associated with a
19% (5–32%) lower mortality rate [15]. Comparisons of
mortality after OPV campaigns with mortality before the
campaigns in other cohorts also indicated lower mortality
for children exposed to OPV campaigns [16, 17], and
adjusted for age, receiving OPV in a campaign was associ-
ated with a 91% (20–99%) lower mortality than not receiv-
ing OPV in a campaign [18].
In two concurrent cluster-randomized controlled tri-
als, we want to assess the separate effect of an MV cam-
paign and an OPV campaign on child health and
survival in the absence of measles and polio infections.
We present the research protocol of each trial: Real-life
Effect of a CAMPaign with a Measles Vaccination
(RECAMP-MV) and Real-life Effect of a CAMPaign with
an Oral Polio Vaccination (RECAMP-OPV). We initi-
ated enrolments into RECAMP-MV in November 2016
and will conduct follow-up until eligibility for a national
measles vaccination campaign (trial completion is ex-
pected by late 2019). We initiated enrolments into
RECAMP-OPV in March 2017 and will conduct follow-
up until eligibility for any national vaccination campaign
or a maximum of 12 months (trial completion is
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board consisting of a statistician, a pediatrician, and an




RECAMP-MV: To assess the real-life effect of an MV
campaign among children aged 9–59 months on non-
accidental mortality or non-accidental morbidity (com-
posite outcome) in rural Guinea-Bissau, where measles
infection is limited. We will test whether an MV cam-
paign can reduce the composite outcome by 30% during
an average follow-up period of 18 months.
RECAMP-OPV: To assess the real-life effect of an
OPV campaign among children aged 0–8 months on
non-accidental mortality or non-accidental morbidity
(composite outcome) in rural Guinea-Bissau, where no
polio circulates. We will test whether an OPV campaign
can reduce the composite outcome by 25% during an
average follow-up period of 10 months.
Secondary objectives
To better understand the real-life effect of either cam-
paign on child health and survival we will also assess the
effect of each campaign on other health measures and




Guinea-Bissau’s Ministry of Health has implemented na-
tional MV campaigns among children aged 9–59months
every third year since 2006 [19], and OPV campaigns
more frequently [15]. Despite some fluctuations in re-
ported measles infection cases [20] and MV coverage
[21], Guinea-Bissau has a low risk profile of measles
(Table 1) and the last recorded case of indigenous wild
poliovirus in Guinea-Bissau was in 1999 [22].
Bandim Health Project (BHP) follows women of fertile
age and children under-five in Guinea-Bissau’s rural
population through a health and demographic surveil-
lance system (HDSS). This enables assessment of child
mortality and morbidity. In Guinea-Bissau’s nine rural
health regions (Oio, Biombo, Gabu, Cacheu, Bafata,
Quinara, Tombali, Bubaque, and Bolama), 222 randomlyTable 1 Measles infection cases, vaccination coverage and vaccinati
data [20, 21]
Year 2008 2009* 2010
Measles infection cases (number) 12 0 26
1st routine measles dose (proportion) 64% 79% 78%
*Guinea-Bissau’s Ministry of Health implemented a national measles vaccination cam
Abbreviation: WHO=World Health Organizationselected geographical clusters with more than 22,000
children under-five are being monitored. The selection
process of the geographical clusters has been described
elsewhere [23]. Field teams conduct regular visits to all
villages in all clusters. At household visits field assistants
register pregnancies, and children’s vaccination status,
mortality, morbidity, nutritional status, campaigns with
other health interventions, migration, and whereabouts
if absent [23]. This is the implementation platform of
RECAMP-MV and RECAMP-OPV.
Design and randomization
The 222 village clusters were randomized to intervention
or control clusters stratified by region and access to
health services. We defined health service access as vac-
cination coverage by 12months of age assessed among
children aged 12–23 months [24], using BHP HDSS data
from 2015 to 2016. This pre-trial vaccination coverage
was based on Bacillus Calmette Guerin (BCG) vaccine,
three doses of OPV, three doses of Pentavalent (diph-
theria, tetanus, pertussis, hepatitis B, haemophilus influ-
enza type B), and MV. We defined low and high pre-
trial vaccination coverage using the median as a cut-off
point. Within each of the two coverage strata per region,
we assigned one half of the clusters to receive interven-
tion and health check-up, and the other half to receive
only health check-up, based on an externally generated
random number.
Study population
Children living in BHP’s rural HDSS are eligible to enter
RECAMP-MV if 9–59 months of age and RECAMP-
OPV if 0–8 months of age. A child is excluded if it: 1) is
considered overtly ill by the enrolling nurse or 2) has an
axillary temperature > 39 °C or 3) is aged > 6months and
has a mid-upper-arm-circumference < 110 mm or 4) has
experienced an allergic reaction after a prior vaccination
or 5) is followed in another ongoing BHP trial in rural
Guinea-Bissau (i.e. children from RECAMP-OPV will
not be enrolled into RECAMP-MV once they turn 9
months old, and children who are < 2 months old and
enrolled in a randomized trial giving BCG and OPV at a
home visit shortly after birth [25] will not be enrolled
into RECAMP-OPV). Criteria 1–4 ensure that we avoid
enrolment of severely acutely ill or immunocomprom-
ised children, and these criteria are based on WHOon campaigns in Guinea-Bissau according to WHO’s country
2011 2012* 2013 2014 2015* 2016 2017
0 0 0 1 153 0 11
78% 90% 89% 81% 90% 71% 66%
paign
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into local practice. Criteria 5 is set to avoid data inter-
pretative issues.Intervention
RECAMP-MV: We offer one dose of a WHO pre-
qualified monovalent live attenuated measles vaccine
(Edmonston-Zagreb strain from Serum Institute of
India) to children aged 9–59months in intervention
clusters.
RECAMP-OPV: We offer one dose of a WHO prequa-
lified standard bivalent OPV to children aged 0–8
months in intervention clusters. To mimic the way most
OPV campaigns are implemented, we initiated the
RECAMP-OPV trial with two visits one month apart
where logistically feasible. At the second visit, a second
dose of OPV is offered to children in intervention clus-
ters, while children in both control and intervention
clusters are health examined and weighed.
The cold chain for both vaccines is documented. We
provide the MV and OPV campaign vaccinations inde-
pendently from Guinea-Bissau’s routine child vaccin-
ation program [26] (Fig. 1).Blinding
It is common practice in Guinea-Bissau that when a
mother/guardian visits the health system with a sick child,
the mother/guardian brings the child’s vaccination card; it
could be speculated that health system personnel give low
treatment priority to children with high vaccination cover-
age and vice versa. Thus, to avoid the risk of differential
treatment decision by health system personnel, we do not
register cluster assignment on the children’s vaccination
cards.Fig. 1 Guinea-Bissau’s routine child vaccination programSample size considerations
RECAMP-MV: Children are followed from enrolment
and until eligibility for a national MV campaign. We aim
to have minimum 80% power to detect at least a 30% re-
duction in non-accidental mortality or non-accidental
morbidity (composite outcome) given that this is the
true reduction during an average follow-up period of 18
months. The planned sample size was originally based
on 182 clusters and a composite outcome rate of 20/
1000 person-years among children aged 9–59 months in
BHP’s rural HDSS. Based on Hayes and Moulton’s
power formula for a cluster-randomized trial [27], our
initial power calculations indicated 86% power to detect
at least a 30% reduction if we enrolled 14,500 children
(with a between cluster variation coefficient of 0.25 and
a harmonic mean (reciprocal of the arithmetic means of
the reciprocals) of total projected accumulated observa-
tion time per cluster of 107 person-years at risk). After
discussions with our data safety and monitoring board
we decided to re-evaluate the power calculations for
both trials when more information on outcome rates
and distribution of enrolments between the clusters was
gained, to verify total enrolments needed. This re-
evaluation was based on data from the first complete
round of enrolment and follow-up visit. As Table 2
shows for RECAMP-MV, we observed a lower compos-
ite outcome rate and harmonic mean of total projected
accumulated observation time per cluster, than expected.
Our data safety and monitoring board supported our de-
cision to enlarge the number of clusters from 182 to
222. This increased the planned enrolments from 14,500
to 18,000 children which gives us 80% power to detect a
30% reduction in the composite outcome (with an as-
sumed control cluster outcome rate of 17/1000 person-
years at risk and a harmonic mean of total projected
Table 2 Sample size estimates derived from the first complete
round of enrolment and follow-up visit of RECAMP-MV and
RECAMP-OPV
RECAMP MV OPV











15/1000 pyrs* 48/1000 pyrs**
Harmonic mean of total
projected accumulated
observation time per cluster
84 pyrs 40 pyrs
Expected reduction 30% 25%
Power 80% 80%
*Assuming that our observed composite outcome rate (15/1000 pyrs) is an
average of the rates in our control and intervention clusters, and that the real
difference between the clusters is 30%, we assumed the rates to be 17/1000
pyrs in control clusters and 12/1000 pyrs in intervention clusters when re-
evaluating our power calculations
**Assuming that our observed composite outcome rate (48/1000 pyrs) is an
average of the rates in our control and intervention clusters, and that the real
difference between the clusters is 25%, we assumed the rates to be 55/1000
pyrs in control clusters and 41/1000 pyrs in intervention clusters when re-
evaluating our power calculations
Abbreviation: Pyrs = person-years at risk
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years at risk).
RECAMP-OPV: Children are followed from enrolment
and until eligibility for any national vaccination cam-
paign or for a maximum of 12months. We aim to have
minimum 80% power to detect at least a 25% reduction
in non-accidental mortality or non-accidental morbidity
(composite outcome) given that this is the true reduc-
tion during an average follow-up period of 10 months.
The planned sample size was originally based on 182
clusters and a composite outcome rate of 70/1000
person-years among children aged 0–8 months in BHP’s
rural HDSS. Based on Hayes and Moulton’s power for-
mula for a cluster-randomized trial [27], our initial
power calculations indicated 80% power to detect at
least a 25% reduction if we enrolled 6500 children (with
a between cluster variation coefficient of 0.25 and a har-
monic mean (reciprocal of the arithmetic means of the
reciprocals) of total projected accumulated observation
time per cluster of 40 person-years at risk). After the re-
evaluation we observed a lower composite outcome rate
than expected. We enlarged the number of clusters from
182 to 222 and increased the planned number of enrol-
ments from 6500 to 10,000 children which gives us 80%
power to detect a 25% reduction in the composite out-
come (with an assumed control cluster outcome rate of55/1000 person-years at risk and a harmonic mean of
total projected accumulated observation time per cluster
of 40 person-years at risk).
Table 2 summarizes the final sample size calculation
estimates for both trials.Enrolment and follow-up procedures
A pilot phase was initiated in Biombo from November
2016 to March 2017. We trained three field teams, each
consisting of at least four field assistants and one enrolling
nurse. The consent process, structured interviews during
enrolment, and structured interviews during follow-up
take place in Portuguese Creole managed by the field
teams (interview questions are written in Portuguese and
based on BHP’s rural HDSS questionnaires used in previ-
ous studies). If necessary, a villager is called to act as a
translator.
For RECAMP-MV, we plan 2–3 enrolment rounds to
visit children who were not home at a previous enrol-
ment visit, or who later move into BHP’s rural HDSS
area. For RECAMP-OPV more enrolment rounds are
needed. The written consent process is two phased: 1) a
field assistant conducts a household visit where he ex-
plains to the mother/guardian of an eligible and present
child that, “In the past the Ministry of Health has pro-
vided many MV and OPV campaigns as the mother/
guardian probably remembers. Now there is rarely any
measles infection and no polio infection in Guinea-
Bissau. Therefore, in the future, the campaigns may stop.
BHP wants to know if it is good for children’s health to
stop or continue MV and OPV campaigns. To know
this, we will vaccinate in some but not other villages.
When the work is done all children aged >9 months in
the villages that do not receive vaccines today will be of-
fered MV. If you are interested your child should be
brought to our health post today”, the field assistant
does not inform the mother/guardian about cluster as-
signment when referring to the health post. 2) at the
health post an enrolling nurse/field assistant carefully
explains both trials, usually to several mothers/guardians
at a time. If a mother/guardian is illiterate a witness in-
dependent from the field team is called. After the ex-
planation, any questions from the mothers/guardians are
welcomed. If mothers/guardians want their children to
participate they are requested to give their signatures/
fingerprints on a consent form and then they receive an
information letter written in Portuguese.
After consent, the enrolling nurse performs a health
check-up of one child at a time (assessing illness, issues
with prior vaccination, and measuring axillary temperature,
mid-upper-arm-circumference, and weight). If the enrolling
nurse experiences that a child is overtly ill, the child’s
mother/guardian is given health advice, and if necessary
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signment. Overtly ill children are offered enrolment at a
subsequent visit, if recovered.
If a child is assessed healthy in intervention clusters,
the child aged 9–59 months is administered a 0.5 ml
reconstituted MV from a 10-dose vial by deep subcuta-
neous injection into the left subscapular region (leftover
doses are discarded six hours after reconstitution), and
the child aged 0–8 months is administered two oral
drops of OPV from a multi-dose vial (leftover doses are
discarded after 28 days). If a child is assessed healthy in
control clusters, the child is not administered MV or
OPV.
All enrolled children are followed through regular
household visits by field assistants who collect infor-
mation on death and hospitalization, among other.
The visits are conducted every two months to chil-
dren < 12 months of age in Oio, Biombo and Cacheu
for logistical reasons, and every six months to older
children, and in the remaining regions. If a field as-
sistant registers the death of a child, a specially
trained field assistant conducts a verbal autopsy at a
subsequent visit [28]. An extra follow-up visit is con-
ducted among a subgroup of enrolled children one-
two months after enrolment; the mothers/guardians
of these children are visited by field assistants to col-
lect information on outpatient visit and maternally re-
ported illness in the elapsed time span. This visit is
also utilized to provide a second OPV dose to chil-
dren aged 0–8 months in intervention clusters. Fig-
ure 2 shows the flow from eligibility to follow-up in
RECAMP-MV and RECAMP-OPV.Outcomes
The primary outcome for each trial is defined as a com-
posite outcome to ensure sufficient power. It consists of:
 non-accidental mortality or
 non-accidental morbidity (first non-fatal
hospitalization with overnight stay)
The secondary outcomes assess other health measures.
They consist of:
 non-accidental mortality
 non-accidental repeated morbidity (at least one non-
fatal hospitalization with overnight stay)
 cause-specific primary outcome (malaria, diarrhea,
and respiratory infections [29])
 proportion of non-accidental outpatient visits and
non-accidental maternally reported illnesses in a
sub-group 1–2 months after enrolment in the
elapsed time span Furthermore in RECAMP-OPV: weight at the extra
follow-up visit 1–2 months after enrolmentAdverse reactions
RECAMP-MV: Common mild adverse reactions to MV
include injection site reactions (within 24 h), fever
(within 7–12 days), or rash (within 7–10 days); all resolve
within 1–3 days. Except from febrile seizures, severe
adverse reactions are extremely rare (anaphylaxis,
thrombocytopenia, and encephalomyelitis) [30]. MV
campaigns’ safety profile has been evaluated, and severe
adverse reactions seem rare [31–35].
RECAMP-OPV: Common mild adverse reactions to
OPV include self-limiting diarrhoea [36]. The only se-
vere adverse reaction is vaccine derived polio, which
occurs in 2–4 infants in a birth cohort of one million
children receiving 4 doses of OPV during the first
months of life [11]. The risk of circulating vaccine de-
rived polio has been markedly lowered with the shift
from trivalent (type 1–2-3) to bivalent OPV (type 1 and
3) [37], as 94% of the circulating vaccine derived polio
was caused by type 2 [38].
To the extent possible, we are in contact with the ad-
verse events following immunization (AEFI) responsible
from each region to register any potential adverse reac-
tion caused by our campaigns.Data management
Data collected by the field teams is transported back to
Bissau regularly. Data entry assistants enter the data in
DBASE, and they also clean the data based on pre-
specified cleaning programs. Data collected during the
pilot phase will be included in the analyses to obtain
sufficient power. Through crosslinks with other data
sources, key variables are verified and data entry errors
are captured.Statistical analyses
Statistical analyses will be performed in STATA by the
research group based on data analysis plans which have
been reviewed by the data safety and monitoring board
(Additional file 1 (RECAMP-MV) and Additional file 2
(RECAMP-OPV)). If further analyses are planned due to
new knowledge arising during the trials, potential
amendments to the respective data analysis plan will be
discussed with the data safety and monitoring board.
We will analyse all primary and secondary outcomes
based on individual level data as the cluster size varies.
We will present confidence intervals of 95%. Absolute
numbers of missing values will be presented, when rele-
vant. No missing values will be imputed. No corrections
will be made for multiple testing.
Fig. 2 Flowchart from eligibility to follow-up in RECAMP-MV and RECAMP-OPV. Abbreviations: MV =measles vaccination; OPV = oral polio
vaccination; MUAC =mid-upper-arm circumference; Y/N/U = yes/no/unknown
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The main conclusion in RECAMP-MV and RECAMP-
OPV will be based on a per-protocol analysis. The pri-
mary outcome will be analyzed in a Cox proportionalhazards model, adjusted by region, pre-trial vaccination
coverage, and sex, with age as the underlying timescale.
We will use cluster-robust standard errors to account
for intra-cluster correlation. Children will enter the
Varma et al. BMC Public Health         (2019) 19:1506 Page 8 of 12analysis on the day of enrolment, and their follow-up
will be censored at:
RECAMP-MV: death due to accident, migration or
eligibility for a national MV campaign, whichever
comes first.
RECAMP-OPV: death due to accident, migration,
eligibility for any national vaccination campaign, or a
maximum of 12 months of follow-up, whichever comes
first.
In both trials, hospital admissions due to accidents are
ignored but the follow-up time is censored while the
child is admitted.
Secondary outcomes
In per-protocol analyses, we will assess the secondary
outcomes: non-accidental mortality, non-accidental re-
peated morbidity, and cause-specific primary outcome.
These secondary outcomes will be analyzed in Cox pro-
portional hazards models as described for the primary
outcome. Furthermore, we will analyse outpatient visits
and maternally reported illnesses occurring 1–2months
after enrolment in per-protocol analyses using log-
binomial regression models adjusted for region, pre-trial
vaccination coverage, and sex. In RECAMP-OPV, we
will furthermore analyze weight and MUAC 1–2months
after enrolment using multiple regression models ad-
justed for region, pre-trial vaccination coverage, and sex.
Effect modifier analyses of primary outcome
In per-protocol analyses we will assess potential effect
modifiers of the primary outcome (Tables 3 and 4).
Sensitivity analyses of primary outcome
We will assess the robustness of the primary analysis of
the primary outcome for each campaign under different
scenarios:
 two intention-to-treat analyses: 1) in a classic
intention-to-treat analysis children will be includedTable 3 RECAMP-MV - potential effect modifiers
Effect modifiers Rationale
Prior MV status Prior MV administration may le
morbidity than no prior MV ad
Sex Girls may experience a larger r
boys [40–43]
Season Enrolment in the dry season m
accidental morbidity than enro
Campaigns with other health interventions Vitamin A may amplify a bene
polio vaccination [42], and ora
difference. Participation status
for campaigns with other healif present in the cluster from the day they were first
potentially eligible to enter but did not because they
e.g. did not receive the assigned treatment, were ex-
cluded due to illness, did not have a mother/guard-
ian to escort them, or had a mother/guardian who
refused participation, 2) in an extended intention-to-
treat analysis children will be included if living in
the cluster from the day they were first potentially
eligible to enter (including children from the classic
intention-to-treat analysis and children who were
absent/travelling) as either campaign may affect
other children’s health in the community by redu-
cing the general infectious pressure.
 Furthermore, we will assess if different censoring
criteria affect the robustness of the resultsEthics and dissemination
Prior to initiating the trials, we obtained ethical approval
from Guinea-Bissau’s national ethics committee (Comité
Nacional de Ética na Saúde: CNES/2016/020) and
consultative approval from Denmark’s national ethics
committee (Den Nationale Videnskabsetiske Komité:
1606756). Then we met with all regional health director-
ates to inform them about the trials’ aim, routines, initi-
ation date, and to request their collaboration. This paper
includes amendments resulting from our discussions with
the data safety and monitoring board and the sample size
enlargements. For these amendments, we obtained ethical
approval from Guinea-Bissau’s national ethics committee
(Comité Nacional de Ética na Saúde: CNES/2018/028)
and consultative approval from Denmark’s national ethics
committee (Den Nationale Videnskabsetiske Komité:
1606756). The trials are registered at www.clinicaltrials
gov.com (identifier NCT03460002). Data is being stored
according to a general agreement between the BHP, and
the Ministry of Health in Guinea-Bissau, and Statens
Serum Institut in Denmark. At the BHP’s main office in
Guinea-Bissau all questionnaires are physically stored, and
databases with enrolment and follow-up information are
separately stored at an encrypted server.ad to a larger reduction in non-accidental mortality/non-accidental
ministration [13, 14, 39, 40]
eduction in non-accidental mortality/non-accidental morbidity than
ay lead to a larger reduction in non-accidental mortality/non-
lment in the rainy season [29, 44]
ficial non-specific effect [45]. Inactivated meningitis A and inactivated
l polio vaccination [17, 46], may neutralize/invert a between cluster
will be assigned on an ecological level, assuming that children eligible
th interventions receive these interventions on the campaign dates.
Table 4 RECAMP-OPV - potential effect modifiers
Effect modifiers Rationale
Sex Previous studies have demonstrated that the effect of OPV is stronger in boys than girls [4, 15, 47].
One vs two doses (2nd dose 1 month after
enrolment)
Observational studies indicate that additional doses of OPV offer additional benefits [15].
Age at first dose of OPV A prior study has indicated that the effect of subsequent vaccines may vary with the age at which
the gut was primed [16].
Season of enrolment Some interventions (eg MV and Vitamin A) have stronger effects when given in the dry season
[29, 48]. We will investigate whether the effect of OPV varies for children enrolled in the dry season
(December–May) versus children enrolled in the rainy season (June–November)
Vitamin A supplements Vitamin A supplementation may amplify the NSEs of vaccines [49, 50]. We will examine whether
the effect of OPV vary before and after being eligible for vitamin A supplementation after enrolment
Prior OPV campaign Repeated doses of OPV offer additional benefits [15]. If OPV campaigns take place during the study,
we will assess whether the effect is similar in children having been exposed/not exposed to prior OPV
campaigns.
Varma et al. BMC Public Health         (2019) 19:1506 Page 9 of 12We will disseminate the results regardless of positive
or negative findings. We intend to publish the results in
internationally peer-reviewed journals. We will provide
the results to WHO, and Guinea-Bissau’s Primary
Health Program, Institute of Public Health and regional
health directorates; the Institute of Public Health will re-
ceive a copy of the results. Any significant deviations
from this paper will be documented in the reported
results.
Discussion
This paper presents the methodology of two concurrent
cluster randomized controlled trials named RECAMP-MV
and RECAMP-OPV. We will assess the real-life effect of
an MV campaign among children aged 9–59months
(RECAMP-MV) and the real-life effect of an OPV cam-
paign among children aged 0–8months (RECAMP-OPV)
on non-accidental mortality or non-accidental morbidity
(composite outcome) in rural Guinea-Bissau, where mea-
sles infection is limited and no polio circulates. Major
strengths lie within the cluster randomisation design
which allows us to assess each campaign’s effect on the
general infectious pressure, which would not be possible
with individual randomisation. Furthermore, the BHP’s
rural HDSS ensures a reliable and thoroughly tested data
collection and data management infrastructure minimiz-
ing the risk of loss to follow-up. In the following, we con-
sider a major limitation, circumstantial challenges, and
future perspectives.
The major limitation is insufficient blinding. Only
blinding health system personnel can make the cam-
paigns appear to have an effect that does not solely de-
pend on the campaigns. However, blinding the research
group, field teams and mothers/guardians would require
placebo use. Administering another vaccine may trigger
NSEs, which could obscure the assessment of the cam-
paigns’ NSEs. Administering saline would be causing
many children pain without benefit. However, as deathand hospitalization are not subjective, and as their as-
sessment is based on standardized interviews, we expect
the risk of differential outcome reporting to be mini-
mized. Though, we do have some speculations about the
potential impact of not blinding the mothers/guardians:
1) mothers/guardians in intervention clusters may con-
sider their children as being extra healthy because they
have seen their children receive the campaign vaccines.
This could make the mothers/guardians less prone to
seek help from the health system if their children get ill.
Thus, among children whose mothers/guardians state
that their children have been ill after enrolment we will
assess the proportion of children whose mothers/guard-
ians also state an outpatient visit by cluster assignment.
2) mothers/guardians in intervention clusters could
come to know that their children belong to an interven-
tion cluster prior to enrolment because there is no allo-
cation concealment. This could make the mothers/
guardians in intervention clusters more motivated to let
their children enrol than mothers/guardians in control
clusters. Thus, we will assess if there is a difference in
the proportion of children whose mothers/guardians
choose not to participate for different reasons, by cluster
assignment.
We could face some circumstantial challenges. For
RECAMP-MV: 1) Guinea-Bissau’s low risk profile makes
a measles epidemic seem unlikely. It is nevertheless pos-
sible. Our regular contact to the AEFI and disease sur-
veillance responsible in the health regions also ensures
registration of suspected measles infection cases. How-
ever, declared measles infection cases are likely to be
misclassifications of other childhood infections as BHP
has experienced in previous studies from Guinea-Bissau.
Therefore, only reported measles infection cases when
regional health directorates confirm circulating measles
will be classified as measles. In such instances, field as-
sistants are instructed to pose questions about symp-
toms, timing, and source of infection based on BHP’s
Varma et al. BMC Public Health         (2019) 19:1506 Page 10 of 12rural HDSS questionnaires used in previous studies. 2) if
Guinea-Bissau’s Ministry of Health does not announce a
national MV campaign during the trial, we will conduct
a visit to all children enrolled in control clusters to offer
them MV after both trials have ended. For RECAMP-
OPV: national OPV campaigns implemented during the
trial will shorten the follow-up period, which could re-
duce the power.
In both trials, it may influence enrolment efficiency
that we exclude children from other ongoing BHP trials
in rural Guinea-Bissau. However, we expect to have in-
cluded a sufficient number of clusters to avoid under-
powering due to this potential challenge.
If RECAMP-MV and/or RECAMP-OPV demonstrate
beneficial NSEs of the expected respective magnitudes in
the absence of measles and/or polio infections, it will
clearly challenge two understandings. Firstly, MV and/or
OPV only prevent measles and/or polio infections. Sec-
ondly, once measles and/or polio infections are eradi-
cated MV and/or OPV campaigns can be phased out,
saving resources and without any negative implications
for child health and survival; phasing out the smallpox
vaccine seems to have had an impact on survival in both
high [51] and low-income countries [52, 53]. Further-
more, demonstrated beneficial NSEs in RECAMP-OPV
will highlight the need to identify alternative ways to
keep stimulating the immune system after the discon-
tinuation of OPV in routine vaccination program
services.
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